Condition
Recurrent Osteosarcoma clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Recurrent Osteosarcoma clinical trials that are recruiting, at sites in 2 countries (most in United States (5), Canada (1)). By phase: Phase 1/2 (2), Phase 2 (2), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest Recurrent Osteosarcoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| FH-FOLR1 CAR T cell therapy for advanced or recurrent osteosarcoma | Phase 1 | Seattle, Washington | Recruiting | Nov 12, 2025 |
| Combining atezolizumab and cabozantinib for treating recurrent or metastatic osteosarcoma in adolescents and young adults | Phase 2 | Boston, Massachusetts and 1 other locations | Recruiting | Aug 25, 2021 |
| Onivyde combined with talazoparib or temozolomide for children and young adults with recurrent solid tumors and Ewing sarcoma | Phase 1/2 | Palo Alto, California and 9 other locations | Recruiting | May 25, 2021 |
| Tegavivint treatment for recurrent or refractory solid tumors in children | Phase 1/2 | Birmingham, Alabama and 20 other locations | Recruiting | Apr 20, 2021 |
| Trastuzumab Deruxtecan for Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor | Phase 2 | Birmingham, Alabama and 31 other locations | Recruiting | Nov 5, 2020 |
All recruiting trials (5)
-
FH-FOLR1 CAR T cell therapy for advanced or recurrent osteosarcoma
This trial will test whether FH-FOLR1 CAR T cells are safe and what dose works best in people aged 1–75 with advanced, recurrent, or treatment-resistant osteosarcoma.
-
Combining atezolizumab and cabozantinib for treating recurrent or metastatic osteosarcoma in adolescents and young adults
This study tests if combining two medications, atezolizumab and cabozantinib, can help adolescents and young adults with recurrent or metastatic osteosarcoma live longer and feel better.
-
Onivyde combined with talazoparib or temozolomide for children and young adults with recurrent solid tumors and Ewing sarcoma
This will test whether adding talazoparib or temozolomide to Onivyde helps children and young adults whose solid tumors or Ewing sarcoma have come back.
-
Tegavivint treatment for recurrent or refractory solid tumors in children
This study tests if a new intravenous medication called tegavivint can help children with tough-to-treat solid tumors, like Ewing sarcoma and desmoid tumors, by finding the right dose and seeing how well it works.
-
Trastuzumab Deruxtecan for Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
This study tests trastuzumab deruxtecan in children and young adults whose osteosarcoma, Wilms tumor, or desmoplastic small round cell tumor has come back or resisted treatment to see if the drug can help shrink tumors.
Related topics
Quick answers
How many Recurrent Osteosarcoma clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (5 trials), Canada (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2, Phase 2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.